Purple Biotech Ltd ADR (PPBT) Stock Price, Quote & News

Company Profile

Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small...

Industry: Biotechnology

Sector: Healthcare

Phone: 972 3 933 3121

Fax: 972 3 509 7196

Website: purple-biotech.com

Address:

4 Oppenheimer Street, Science Park, Rehovot, Israel

PPBT4LYFE Aug. 21 at 3:36 AM

$PPBT just some casual antisemitism from Smitty. Some of you are truly deplorable.

0 · Reply

Jpurpleteam Aug. 21 at 12:18 AM

$PPBT wen moon? Still holding 😎

0 · Reply

Smittysixty Aug. 20 at 11:59 PM

$PPBT Just another sleepy biotech. 😴💉 50K short shares returned today (now 150K total). Meanwhile, 95% of volume flowed through the dark pool. But sure… no institutional interest. No positioning. Just a worthless little ticker with nothing going on. Nothing to see here, folks. Move along. 👋

2 · Reply

Stocksavior14 Aug. 20 at 5:56 PM

$PPBT yep, dilute, decline, reverse split, dilute decline, reverse split… All while our execs are making INSANE money from a company making $0

0 · Reply

Dr_HIM Aug. 20 at 4:44 PM

$PPBT Lets see if we can hit at least $2.50 tomorrow..

2 · Reply

Jay_tradr Aug. 20 at 3:12 PM

$PPBT this thing still just waiting to get beat by a vaccine, huh? Sweet. Have to say the decline this time has been a bit drawn out lately.... just kidding. We'll see another double digit % haircut soon enough. We always do. Wash, rinse, repeat. Chug along, chug along, chug along, fall off a cliff.... chug along, chug along, This toblerone bar sucks. 🤣😂🤣

0 · Reply

Stocksavior14 Aug. 20 at 2:24 PM

$PPBT this legit may have been a scam the whole time. And Even if the product is real, they are getting shareholders to fund everything at shareholders expense so that their big pharma buddies can come in a scoop it up dirt cheap or even out of bankruptcy. Our exec board grifted everyone!🤣

0 · Reply

Stocksavior14 Aug. 20 at 2:22 PM

$PPBT the lower this goes, the more bullish the permabull idiots are

0 · Reply

Stocksavior14 Aug. 20 at 2:22 PM

$PPBT bulls would love that. Super bullish to them. And if this goes under $2 they are going to jump for joy LOL

0 · Reply

Gil2690 Aug. 20 at 1:43 PM

$PPBT so glad i dumped this POS IN 2021

1 · Reply

Purple Biotech Reports Second Quarter 2025 Financial Results

Jul 23, 2025, 7:00 AM EDT - 4 weeks ago

Purple Biotech CEO Issues Letter to Shareholders Highlighting Pipeline Progress and Clinical Milestones Achieved in First Half of 2025

Jun 23, 2025, 7:00 AM EDT - 2 months ago

Purple Biotech Highlights Significant Advantages of the Novel CAPTN-3 Tri-Specific Antibody Platform at the EACR 2025 Annual Congress

May 21, 2025, 7:10 AM EDT - 3 months ago

Purple Biotech Reports First Quarter 2025 Financial Results

May 12, 2025, 7:30 AM EDT - 3 months ago

Purple Biotech Appoints Shai Lankry as Chief Financial Officer

Apr 28, 2025, 8:28 AM EDT - 4 months ago

Purple Biotech Reports Positive NT219 Data at AACR for Colorectal and Head and Neck Cancers

Mar 10, 2025, 8:57 AM EDT - 5 months ago

Purple Biotech Reports Fourth Quarter and Full-Year 2024 Financial Results

Feb 18, 2025, 7:00 AM EST - 6 months ago

Purple Biotech Advances NT219 into Phase 2 Head and Neck Cancer Trial

Dec 5, 2024, 7:13 AM EST - 9 months ago

Purple Biotech Announces Closing of $2.8 Million Registered Direct Offering of American Depositary Shares

Dec 3, 2024, 8:23 AM EST - 9 months ago

Purple Biotech Announces $2.8 Million Registered Direct Offering of American Depositary Shares

Dec 2, 2024, 9:18 AM EST - 9 months ago

Why Is Purple Biotech Stock Trading Higher On Monday?

Nov 15, 2024, 7:00 AM EST - 9 months ago

Purple Biotech Reports Third Quarter 2024 Financial Results

Nov 4, 2024, 7:50 AM EST - 10 months ago

Purple Biotech Identifies Potential New Serum Biomarker for its Lead Oncology Therapeutic Candidate CM24: Associated with 79% Reduction in Risk of Death

Oct 25, 2024, 7:20 AM EDT - 10 months ago

Purple Biotech Presents New Data for its Novel Tri-Specific T Cell and NK Cell Engagers Antibody Platform, CAPTN-3, at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Oct 10, 2024, 7:30 AM EDT - 11 months ago

Purple Biotech to Present Data for its Tri-Specific Antibody Platform—CAPTN-3—at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Sep 18, 2024, 6:30 AM EDT - 1 year ago

Purple Biotech Reports Additional Positive Interim Data from its Randomized Phase 2 Study with its Lead Oncology Therapeutic Candidate CM24

Aug 30, 2024, 7:00 AM EDT - 1 year ago

Purple Biotech to Participate at H.C. Wainwright 26th Annual Global Investment Conference

Aug 16, 2024, 8:12 AM EDT - 1 year ago

Purple Biotech Reports Second Quarter 2024 Financial Results and Business Highlights

Jul 25, 2024, 7:35 AM EDT - 1 year ago

Purple Biotech Receives Extension to Regain Compliance with the Nasdaq's Minimum Bid Price Rule

Jul 10, 2024, 7:30 AM EDT - 1 year ago

Purple Biotech to Host Virtual KOL Event to Discuss Positive Interim Results from Phase 2 Pancreatic Cancer Study with CM24 on July 11, 2024

Jul 2, 2024, 4:00 PM EDT - 1 year ago

Purple Biotech Announces Closing of Exercise of Warrants for $2 Million Gross Proceeds

Jul 1, 2024, 9:00 AM EDT - 1 year ago

Purple Biotech Announces Exercise of Warrants for $2 Million Gross Proceeds

Jun 27, 2024, 7:45 AM EDT - 1 year ago

Purple Biotech Reports Additional Positive Interim Results from its Randomized Phase 2 Pancreatic Cancer Study with CM24 Regarding a Potential Predictive Biomarker for Overall Survival Benefit

Jun 1, 2024, 8:00 AM EDT - 1 year ago

Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic Cancer

May 21, 2024, 7:30 AM EDT - 1 year ago

Purple Biotech Reports First Quarter 2024 Financial Results

Apr 25, 2024, 7:00 AM EDT - 1 year ago

Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting

Mar 14, 2024, 7:30 AM EDT - 1 year ago

Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology

Mar 5, 2024, 7:55 AM EST - 1 year ago

Purple Biotech Reports Fourth Quarter and Full-Year 2023 Financial Results

Feb 27, 2024, 7:00 AM EST - 1 year ago

Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024

Feb 13, 2024, 7:00 AM EST - 1 year ago

Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 Trial

Feb 1, 2024, 7:30 AM EST - 1 year ago

Purple Biotech Reaches Recommended Phase 2 Dose for NT219

Dec 20, 2023, 8:05 AM EST - 1 year ago

Purple Biotech Appoints Dr. Yael Margolin to its Board of Directors

Dec 14, 2023, 6:50 AM EST - 1 year ago

Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial

Nov 21, 2023, 6:50 AM EST - 1 year ago

Purple Biotech Reports Third Quarter 2023 Financial Results

Oct 19, 2023, 3:55 PM EDT - 1 year ago

Purple Biotech Announces Closing of $5 Million Registered Direct Offering

Oct 17, 2023, 8:00 AM EDT - 2 years ago

Purple Biotech Announces $5 Million Registered Direct Offering

Oct 6, 2023, 7:50 AM EDT - 2 years ago

Purple Biotech Reports Potential Biomarker Data Support CM24's Mechanism of Action

Oct 3, 2023, 7:50 AM EDT - 2 years ago

Purple Biotech Reports Positive Interim and Preliminary Results from NT219 Phase 1/2 Study in R/M Head & Neck Cancer

Aug 22, 2023, 9:29 AM EDT - 2 years ago

Purple Biotech Reports Second Quarter 2023 Financial Results

Jul 11, 2023, 8:15 AM EDT - 2 years ago

Purple Biotech Reports Positive Results of CM24 Dose Escalation in Advanced Pancreatic Cancer Patients

May 16, 2023, 4:00 PM EDT - 2 years ago

Purple Biotech Reports First Quarter 2023 Financial Results and Provides Business Update

Apr 19, 2023, 8:15 AM EDT - 2 years ago

Purple Biotech Reports New Preclinical Data on Potential of NT219 to Re-sensitize Resistant Tumors to Immune Checkpoint Inhibitors

Apr 18, 2023, 7:00 AM EDT - 2 years ago

Purple Biotech to Participate in Canaccord Genuity's 2023 Horizons in Oncology Virtual Conference

Mar 24, 2023, 7:00 AM EDT - 2 years ago

Purple Biotech Reports Temporary Medical Leave of CEO Gil Efron

Feb 14, 2023, 7:01 AM EST - 2 years ago

Purple Biotech Announces First Patient Dosed in Open Label, Randomized Part of CM24 Phase 2 Clinical Trial

Feb 8, 2023, 7:12 AM EST - 2 years ago

Purple Biotech Reports Fourth Quarter and Full-Year 2022 Financial Results

Nov 15, 2022, 7:00 AM EST - 3 years ago

Purple Biotech Presents New Data on Mechanism of Action for CM24 at the AACR Special Conference: Cancer Metastasis

Nov 8, 2022, 7:53 AM EST - 3 years ago

Purple Biotech Reports Third Quarter 2022 Financial Results

Nov 2, 2022, 7:37 AM EDT - 3 years ago

Purple Biotech Appoints Lior Fhima as Chief Financial Officer

Aug 4, 2022, 7:30 AM EDT - 3 years ago

Purple Biotech Reports Second Quarter 2022 Financial Results

PPBT4LYFE Aug. 21 at 3:36 AM

$PPBT just some casual antisemitism from Smitty. Some of you are truly deplorable.

0 · Reply

Jpurpleteam Aug. 21 at 12:18 AM

$PPBT wen moon? Still holding 😎

0 · Reply

Smittysixty Aug. 20 at 11:59 PM

2 · Reply

Stocksavior14 Aug. 20 at 5:56 PM

$PPBT yep, dilute, decline, reverse split, dilute decline, reverse split… All while our execs are making INSANE money from a company making $0

0 · Reply

Dr_HIM Aug. 20 at 4:44 PM

$PPBT Lets see if we can hit at least $2.50 tomorrow..

2 · Reply

Jay_tradr Aug. 20 at 3:12 PM

0 · Reply

Stocksavior14 Aug. 20 at 2:24 PM

0 · Reply

Stocksavior14 Aug. 20 at 2:22 PM

$PPBT the lower this goes, the more bullish the permabull idiots are

0 · Reply

Stocksavior14 Aug. 20 at 2:22 PM

$PPBT bulls would love that. Super bullish to them. And if this goes under $2 they are going to jump for joy LOL

0 · Reply

Gil2690 Aug. 20 at 1:43 PM

$PPBT so glad i dumped this POS IN 2021

1 · Reply

St0ckPwn Aug. 20 at 10:10 AM

$PPBT we officially hit 0 lol

1 · Reply

Stocktelligence Aug. 19 at 4:35 PM

$PPBT hi 2.19 old friend

2 · Reply

Dr_HIM Aug. 19 at 3:32 PM

$PPBT 🥱🤖

1 · Reply

Purplepayday Aug. 19 at 3:09 PM

$PPBT I guess that you all know that if this ticker is getting a pump then it will be because of more dilution again…. So the tutes (that have less than 2% of outstanding shares) will be dumping their shares from the offering on retail again, just like they always have been doing 👍 .. Anyway, they can’t dilute more than a million shares(1/3) before December… Unless they find another loophole like last time with the warrant’s Yes… a partner they might be able to find🤷🏻‍♂️ But that will for sure not come for free (without dilution) because our drugs doesn’t seem to be the Holy Grail🧐

0 · Reply

Smittysixty Aug. 19 at 1:30 PM

$PPBT Who’s really gonna benefit from the next pump? Back in 2020, Jewish “Pizza boy” ran this thing to record highs so the tutes—who owned 80%+ of the float—could unload on retail. Fast‑forward to now… tutes only hold about 3–5%. So why would they pump it just so retail can unload on other retail? That’s not how this game works. They unload at all‑time highs… and they load at all‑time lows. Given they barely own anything now, the next pump feels more like a move to pry shares from retail so they can reload cheap—before that elusive 100 mg NT‑219 data finally drops. So ask yourself: who’s actually set to win from the next “pump” if tutes don’t have much to dump? 🧐

0 · Reply

YamiDawg Aug. 19 at 12:22 PM

$PPBT Come on. After the 1x20 RS and the approved 100 billion shelf. It’s gotta be about time for HCW or another big named back Finacial Analyst to pump us with some BS Fake SP target. Let’s have it already. What will it be this year. I mean after a 1x20 killer $30 is not putting us back to even on our money. Will they predict $500. lol. Nope. Maybe after being so wrong past 5-6 years they will predict $2.50. More realistic.

1 · Reply

Stocksavior14 Aug. 18 at 10:29 PM

$PPBT lol nope, the tutes seem to know less than Smitty 🤣🤣🤣

0 · Reply

Stocksavior14 Aug. 18 at 10:28 PM

$PPBT more and more evidence I guess of this being a scam to line their pockets and their buddies pockets

0 · Reply

Stocksavior14 Aug. 18 at 10:28 PM

$PPBT it won’t be at this rate. Seems this is a dead stock for current shareholders… but the permabulls would say that’s extra bullish

0 · Reply

Purplepayday Aug. 18 at 5:35 PM

$PPBT .. Is it really true that ”Tutes” have been selling close to 500K shares in the last 8-9 month 🤔 Unbelievable, don’t they know what we are worth…. Billions of billions 🧐

0 · Reply

Dr_HIM Aug. 18 at 2:34 PM

$PPBT Pump is programmed in… ⏰

1 · Reply

Dr_HIM Aug. 18 at 2:33 PM

$PPBT 10:10 👇🏽👇🏽

0 · Reply

Market Cap	5.84M
Revenue (ttm)	0.00
Net Income (ttm)	-7.24M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	8,400
Avg Vol	118,140
Day's Range	N/A - N/A
Shares Out	2.59M
Stochastic %K	42%
Beta	0.49
Analysts	Sell
Price Target	$34.00